Wugen
St. Louis, US · Founded 2018 · Delaware corporation · 10 known investors
Allotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
Founders & leadership
AK
Ayman KabakibiExecutive
CT
Cherry ThomasExecutive
KS
Kumar SrinivasanExecutive
KV
Keith VendolaExecutive
DM
Daniel M KempExecutive
MC
Matthew CooperNamed on SEC filing
JK
Jan K DavidsonNamed on SEC filing
Board
NM
DD
Drew DennisonBoard director
NO
BM
BH
Bosun HauBoard director
Investors · 10
Aisling CapitalNew York
Alpha Wave GlobalMiami
BioGenerator VenturesSt. Louis · $50K – $250K
RiverVest Venture PartnersSt. Louis · $500K – $3M
Abingworthreported · 3 sourcesLondon · $15M – $30Mvia Bali Muralidhar · board
Fidelity InvestmentsreportedBoston
Intermediate Capital GroupreportedLondon · $5M – $50M
LYZZ CapitalreportedShanghai
Also in the syndicate · 2
Lightchain CapitalTybourne Capital Management
Funding
SEC filings, press & company announcements$294M disclosed across 4 rounds · 2020–2026
- $35MraisedJul 2026 · 2 sourcesSource ↗
▶$123.3MraisedJul 2026 · 20 investors · Other Health CareRule 506(b)
▶$123.3MraisedJul 2026 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Niall O'DonnellDirector
- Bali MuralidharDirector
- Peter KienerDirector
- Drew DennisonDirector
- Kevin LiDirector
- Bosun HauDirector
- Matthew CooperExecutive Officer
- Ayman KabakibiExecutive Officer
- Natalie MountDirector
- Kumar SrinivasanExecutive Officer, Director
- Cherry ThomasExecutive Officer
- Offering amount
- $163M
- Amount sold
- $123.3M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$98.5MraisedJul 2021 · 27 investors · Other Health CareRule 506(b)
▶$98.5MraisedJul 2021 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel M KempExecutive Officer, Director
- Bali MuralidharDirector
- Ayman KabakibiExecutive Officer
- John P McKearnDirector
- Bosun HauDirector
- Peter KienerDirector
- Jan K DavidsonExecutive Officer
- Matthew CooperExecutive Officer
- Kevin LiDirector
- Drew DennisonDirector
- Offering amount
- $172M
- Amount sold
- $98.5M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$37.2MraisedJul 2021 · 6 investors · Other Health CareRule 506(b)
▶$37.2MraisedJul 2021 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ayman KabakibiExecutive Officer
- Jan K DavidsonExecutive Officer
- Kevin LiDirector
- John P. McKearnDirector
- Matthew CooperExecutive Officer
- Bali MuralidharDirector
- Peter KienerDirector
- Drew DennisonDirector
- Bosun HauDirector
- Daniel M KempExecutive Officer, Director
- Offering amount
- $37.2M
- Amount sold
- $37.2M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Biogen Idec90 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
PepGen64 shared keywordsPepGen develops disease-modifying therapeutics aimed at the underlying causes of serious genetic neuromuscular and neurological diseases. The company is building a pipeline of oligonucleotide-based treatments for these conditions.
Amgen57 shared keywordsAmgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
Urogen42 shared keywordsUroGen is a biopharmaceutical company developing and commercializing treatments for urological cancers, including FDA-approved therapies such as JELMYTO and ZUSDURI built on its RTGel technology. Its pipeline focuses on uro-oncology indications like non-muscle invasive bladder cancer.
Compugen38 shared keywordsCompugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.
NervGen Pharma38 shared keywordsNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
Companies competing with Wugen for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Wugen do?
- Allotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
- Who are Wugen's investors?
- Wugen's investors include Aisling Capital, Alpha Wave Global, BioGenerator Ventures, RiverVest Venture Partners, Abingworth, Fidelity Investments, Intermediate Capital Group, LYZZ Capital.
- How much funding has Wugen raised?
- Wugen has disclosed $294M raised across 4 rounds.
- Where is Wugen headquartered?
- Wugen is headquartered in St. Louis, US.